Why the study?
Does high-dose oral medroxyprogesterone acetate cause hypercoagulability in postmenopausal patients with advanced breast cancer?
Population
12 postmenopausal patients with advanced breast cancer, considered not at risk for thromboembolic disease
Design
Cohort
Follow-up
at least 3 months
Authors
Loading...
Mild procoagulant shifts with high-dose MPA suggest limited thrombotic risk in advanced breast cancer; hypothesis-generating and requires prospective validation.
Does high-dose oral medroxyprogesterone acetate cause hypercoagulability in postmenopausal patients with advanced breast cancer?
High-dose oral medroxyprogesterone acetate induces mild procoagulant changes that remain within normal limits, suggesting low thrombotic risk in patients without additional risk factors.
Brema et al. (1981) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: